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Introduction {#sec001}
============

Schistosomiasis is recognized as a serious public health problem in the world \[[@pone.0225425.ref001],[@pone.0225425.ref002]\]. According to the World Health Organization (WHO), it is estimated that more than 206 million people worldwide are affected by the disease and that more than 700 million people live in areas where the disease is endemic \[[@pone.0225425.ref003]\]. Schistosomiasis is an infection caused by trematodes of the genus Schistosoma and occupies, after malaria, the second position in the world among parasitic infections \[[@pone.0225425.ref004],[@pone.0225425.ref005]\]. This chronic disease is prevalent in tropical and subtropical regions, mainly in regions that lack basic sanitation, allowing the proliferation of contaminating agents, as well as the continuity of people being infected \[[@pone.0225425.ref002],[@pone.0225425.ref003],[@pone.0225425.ref006]\]. In addition, the absence of campaigns that promote health education to the population, as well as the lack of dissemination of epidemiological data, favor the continuity of the disease \[[@pone.0225425.ref006],[@pone.0225425.ref007]\].

The current treatment for schistosomiasis is centered around praziquantel, an acylated quinoline-pyrazine derivative, that is able to act against the main strains of *Schistosoma mansoni* that infect humans and has been used for \>30 years \[[@pone.0225425.ref008]\]. However, the exclusive use of praziquantel has been accompanied with reports in the literature that parasites isolated from some patients have been resistant to pharmacological treatment \[[@pone.0225425.ref009]--[@pone.0225425.ref011]\]. Besides, praziquantel has no effect on immature schistosomes and cannot prevent reinfection or alter the schistosome life cycle \[[@pone.0225425.ref012],[@pone.0225425.ref013]\]. If it is considered that there is no effective alternative for the control of schistosomiasis, it is evident that the risk of developing resistance to praziquantel will increase in the coming decades, being a concern for the medical community. In view of this scenario, research priorities for facing schistosomiasis include the development and testing of new drugs, test combinations of praziquantel with new drugs as well as monitoring the spread of praziquantel drug resistance \[[@pone.0225425.ref001]\].

In view of the need to obtain alternatives for the treatment of schistosomiasis and other neglected diseases, efforts have been made within the medicinal chemistry, using various planning techniques to obtain substances with improved structural characteristics and with less toxicity \[[@pone.0225425.ref014],[@pone.0225425.ref015]\]. These attempts comprehend praziquantel chemical structure modification by synthesis and evaluation of its analogues, rational design of new pharmacophores and discovery of new active compounds from screening programs on a large scale \[[@pone.0225425.ref016]\].

A class of derivatives that has gained attention because of its promising experimental anti-schistosomal activity is the one bearing the thiazole nucleus, which is effective against both immature and adult *S*. *mansoni* worms \[[@pone.0225425.ref017]\]. The thiazole moiety plays an important role in the medicinal chemistry field since it serves as a scaffold for new drug synthesis, being already used as antimicrobial (sulfathiazole), anthelmintic and fungicide (thiabenzadole) and schistosomicide (niridazole) compounds \[[@pone.0225425.ref018]--[@pone.0225425.ref020]\]. Niridazole (Ambilhar®) started being used for treatment in 1964, but patients had little tolerance to this drug with serious side effects due to the presence of nitroaromatic chemical groups that act as parasitophores (their presence is essential to kill the worm) and also cause damage to host DNA by formation of adducts that induce mutagenesis \[[@pone.0225425.ref016]\]. However, advances in the development of medicinal chemistry tools have recently allowed the synthesis of new thiazole derivatives with anti-schistosomal activity. As an example, Santiago *et al*., 2014 \[[@pone.0225425.ref021]\] synthetized a set of molecules whose structures have a hydrazine and/or thiazole nucleus as a common group, and different pharmacophores including thiosemicarbazone, phthalyl thiosemicarbazone, phthalyl thiazole, and phthalyl thiazolidinone. Among them, the compounds comprised of thiazole and phthalimide were the ones that exhibited the highest activity against worms, with a significant decline in motility, pairing and oviposition, as well as a mortality rate of 100% after 144 h of treatment.

Recently, Reddy *et al*., 2018 \[[@pone.0225425.ref022]\] described the synthesis of a library of hydrazinyl-thiazoles via a three-component reaction of various aldehydes/ketones with thiosemicarbazide and different phenacyl bromides, but the authors did not evaluate any biological potential of the derivatives. Based on the potentially promising features of these new compounds, here we selected eight aryl-thiazole derivatives and examined their efficacy in terms of (i) schistosome survival, (ii) egg output (oviposition), (iii) motility, (iv) couples pairing, (v) ultrastructural alterations in the tegument of *S*. *mansoni* as determined by scanning electron microscopy (SEM), and (v) expression of *S*. *mansoni* developmental genes.

Materials and methods {#sec002}
=====================

Chemistry {#sec003}
---------

Synthesis of the compounds bioassayed in this study was previously described \[[@pone.0225425.ref022]--[@pone.0225425.ref024]\]. Production of aryl-thiazole derivatives was carried out at the Laboratory of Chemistry and Therapeutic Innovation, at the Federal University of Pernambuco. Synthesis was carried out in two steps ([Fig 1](#pone.0225425.g001){ref-type="fig"}).

![Route of synthesis to obtain the aryl-thiazole derivatives (NJ series).\
In the compounds, R was hydrogen, 4-chloro, 4-bromo or 4-nitro. For 2,4-dimethoxy-aryl thiazole (right side route) R = Cl for NJ03; R = NO~2~ for NJ06; R = Br for NJ08 and R = H for NJ12. For 3,4,5-trimethoxy-aryl thiazole (left side route) R = Cl for NJ04; R = NO~2~ for NJ05; R = Br for NJ07 and R = H for NJ11.](pone.0225425.g001){#pone.0225425.g001}

In the first step, the thiosemicarbazides (3.2 mmol) reacted in equimolar amounts with 2,4-dimethoxy-benzaldehyde (right side route) or 3,4,5-trimethoxy-benzaldehyde (left side route) through a condensation reaction in the presence of hydrochloric acid as the reaction catalyst to obtain a thiosemicarbazone (TSC), which served as an intermediary for thiazole synthesis following its acquisition. This second step was carried out in the presence of 2-(2,4-dimethoxybenzylidene)thiosemicarbazone (0.62 mmol) or 2-(3,4,5-trimethoxybenzylidene)thiosemicarbazone (0.55 mmol), 1.1 molar equivalent of different 2-chloro or 2-bromoacetophenones (unsubstituted, 4-chloro-phenyl, 4-bromo-phenyl, 4-nitro-phenyl) under basic conditions (4.0 molar equivalent of sodium acetate) and ethanol in reflux \[[@pone.0225425.ref025]\].

Reactions were monitored with analytical thin-layer chromatography in silica gel 60 F254 plates and visualized under UV light (254 nm). Melting points were determined on a Quimis 340 capillary melting point apparatus and were not corrected. IR spectra were measured on Bruker IFS-66 IR spectrophotometer (Bruker, Germany) using KBr pellets. NMR spectra were recorded on Bruker Avance (600 MHz for ^1^H and 150 MHz for ^13^C) instruments. HRMS were performed on a MALDI-TOF Autoflex III (Bruker Daltonics, Billerica, MA, USA). The spectroscopic data of the synthesized compounds (NJ03 to NJ08, NJ11 and NJ12) are in accordance with the structures proposed in [Fig 1](#pone.0225425.g001){ref-type="fig"} and with the spectra published by Reddy *et al*., *2018* \[[@pone.0225425.ref022]\].

### NJ03: (E)-4-(4-chlorophenyl)-2-((E)-(2,4-dimethoxybenzylidene)hydrazono)-2,3-dihydrothiazole {#sec004}

C~18~H~16~ClN~3~O~2~S. Yield: 71.20%. M.P.: 191-192ºC. Rf: 0.44 (7:3 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.80 (s, 6H, OCH~3~); 6.60 (m, 2H, CH-Ar); 7.35 (s, 1H, thiazole); 7.46 (d, 2H, CH-Ar, J = 12 Hz); 7.71 (d, 1H, CH-Ar, J = 6 Hz); 7.83 (d, 2H, CH-Ar, J = 12 Hz); 8.38 (s, 1H, HC = N); 12.30 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 55.94, 56.28, 104.85, 107.07, 115.38, 126.76, 127.93, 129.10, 129.99, 132.86, 139.66, 147.45, 159.19, 162.68, 168.94. IR (KBr, cm^−1^): 1396 (N = C-S), 1459 (C = N), 3317 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~18~H~16~ClN~3~O~2~S: 374.069; found: 374.079.

### NJ04: (E)-4-(4-chlorophenyl)-2-((E)-(3,4,5-trimethoxybenzylidene)hydrazono)-2,3-dihydrothiazole {#sec005}

C~19~H~18~ClN~3~O~3~S. Yield: 61.80%. M.P.: 135-136ºC. Rf: 0.56 (7:3 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.70 (s, 3H, OCH~3~); 3.87 (s, 6H, OCH~3~); 6.99 (s, 2H, CH-Ar); 7.38 (s, 1H, thiazole); 7.47 (d, 2H, CH-Ar, J = 6 Hz); 7.88 (d, 2H, CH-Ar, J = 6 Hz); 7.97 (s, 1H, HC = N); 12.05 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 56.34, 60.59, 104.05, 104.86, 127.67, 129.08, 130.40, 132.39, 134.06, 139.18, 141.76, 149.83, 153.67, 168.87. IR (KBr, cm^−1^): 1326 (N = C-S), 1411 (C = N), 3294 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~19~H~18~ClN~3~O~3~S: 404.079; found: 404.081.

### NJ05: (E)-4-(4-nitrophenyl)-2-((E)-(3,4,5-trimethoxybenzylidene)hydrazono)-2,3-dihydro-thiazole {#sec006}

C~19~H~18~N~4~O~5~S. Yield: 55.20%. M.P.: 212-214ºC. Rf: 0.62 (6:4 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.69 (s, 3H, OCH~3~); 3.86 (s, 6H, OCH~3~); 6.97 (s, 2H, CH-Ar); 7.71 (s, 1H, thiazole); 8.00 (s, 1H, HC = N); 8.10 (d, 2H, CH-Ar, J = 6 Hz); 8.26 (d, 2H, CH-Ar, J = 6 Hz); 12.34 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 56.35, 60.59, 104.12, 109.00, 124.54, 126.79, 129.18, 130.28, 139.25, 141.07, 142.22, 146.66, 153.66, 165.09, 169.13. IR (KBr, cm^−1^): 1345 (N = C-S), 1412 (C = N), 3305 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~19~H~18~N~4~O~5~S: 415.103; found: 415.109.

### NJ06: (E)-2-((E)-(2,4-dimethoxybenzylidene)hydrazono)-4-(4-nitrophenyl)-2,3-dihydrothiazole {#sec007}

C~18~H~16~N~4~O~4~S. Yield: 72.60%. M.P.: 218-220ºC. Rf: 0.68 (7:3 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.81 (s, 6H, OCH~3~); 6.61 (m, 2H, CH-Ar); 7.64 (s, 1H, thiazole); 7.70 (d, 1H, CH-Ar, J = 12 Hz); 8.08 (d, 2H, CH-Ar, J = 6 Hz); 8.24 (d, 2H, CH-Ar, J = 12 Hz); 8.28 (s, 1H, HC = N); 12.09 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 55.86, 56.20, 106.95, 108.56, 115.63, 124.49, 126.54, 126.76, 138.15, 141.16, 146.61, 148.88, 158.96, 162.40, 169.23. IR (KBr, cm^−1^): 1325 (N = C-S), 1413 (C = N), 3172 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~18~H~16~N~4~O~4~S: 385.093; found: 386.100.

### NJ07: (E)-4-(4-bromophenyl)-2-((E)-(3,4,5-trimethoxybenzylidene)hydrazono)-2,3-dihydrothiazole {#sec008}

C~19~H~18~BrN~3~O~3~S. Yield: 65.80%. M.P.: 159-161ºC. Rf: 0.45 (6:4 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.70 (s, 3H, OCH~3~); 3.87 (s, 6H, OCH~3~); 6.98 (s, 2H, CH-Ar); 7.39 (s, 1H, thiazole); 7.61 (d, 2H, CH-Ar, J = 6 Hz); 7.81 (d, 2H, CH-Ar, J = 6 Hz); 7.97 (s, 1H, HC = N); 12.22 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 56.33, 56.52, 60.59, 104.05, 104.96, 120.97, 127.99, 130.39, 131.99, 134.38, 139.17, 141.79, 149.85, 153.66, 168.88. IR (KBr, cm^−1^): 1347 (N = C-S), 1409 (C = N), 3305 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~19~H~18~BrN~3~O~3~S: 448.029; found: 448.032.

### NJ08: (E)-4-(4-bromophenyl)-2-((E)-(2,4-dimethoxybenzylidene)hydrazono)-2,3-dihydrothiazole {#sec009}

C~18~H~16~BrN~3~O~2~S. Yield: 37.10%. M.P.: 173-174ºC. Rf: 0.57 (7:3 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.80 (s, 6H, OCH~3~); 6.60 (m, 2H, CH-Ar); 7.36 (s, 1H, thiazole); 7.60 (d, 2H, CH-Ar, J = 6 Hz); 7.71 (d, 1H, CH-Ar, J = 12 Hz); 7.77 (d, 2H, CH-Ar, J = 12 Hz); 8.36 (s, 1H, HC = N); 12.20 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 55.93, 56.27, 104.87, 107.05, 115.36, 126.71, 128.18, 130.26, 131.73, 132.00, 146.90, 159.13, 162.60, 167.61, 168.94. IR (KBr, cm^−1^): 1278 (N = C-S), 1421 (C = N), 3312 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~18~H~16~BrN~3~O~2~S: 418.018; found: 418.030.

### NJ11: (E)-4-phenyl-2-((E)-(3,4,5-trimethoxybenzylidene)hydrazono)-2,3-dihydrothiazole {#sec010}

C~19~H~19~N~3~O~3~S. Yield: 54.00%. M.P.: 193-195ºC. Rf: 0.52 (7:3 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.70 (s, 3H, OCH~3~); 3.75 (s, 6H, OCH~3~); 6.99 (s, 2H, CH-Ar); 7.31 (d, 2H, CH-Ar, J = 12 Hz); 7.40 (s, 1H, thiazole); 7.42 (d, 1H, CH-Ar, J = 12 Hz); 7.87 (d, 2H, CH-Ar, J = 6 Hz);7.98 (s, 1H, HC = N); 12.22 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 56.22, 56.34, 60.60, 104.03, 125.98, 127.99, 129.07, 130.46, 135.17, 139.14, 141.61, 150.98, 153.67, 168.72. IR (KBr, cm^−1^): 1324 (N = C-S), 1413 (C = N), 3176 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~19~H~19~N~3~O~3~S: 370.118; found: 370.125.

### NJ12: (E)-4-phenyl-2-((E)-(3,4,5-trimethoxybenzylidene)hydrazono)-2,3-dihydrothiazole {#sec011}

C~18~H~17~N~3~O~2~S. Yield: 61.40%. M.P.: 220-222ºC. Rf: 0.46 (7:3 *n*-hexane/ethyl acetate). NMR ^1^H (600 MHz, DMSO) δ: 3.81 (s, 6H, OCH~3~); 6.62 (m, 2H, CH-Ar); 7.27 (s, 1H, thiazole); 7.29 (d, 1H, CH-Ar, J = 12 Hz); 7.40 (t, 2H, CH-Ar, J = 6 Hz); 7.73 (d, 1H, CH-Ar, J = 6 Hz); 7.86 (d, 2H, CH-Ar, J = 6 Hz); 8.28 (s, 1H, HC = N); 11.98 (s, 1H, NH). NMR ^13^C (DMSO, 150 MHz) δ: 55.88, 56.21, 103.65, 106.97, 115.85, 126.00, 126.51, 128.45, 129.03, 135.28, 137.56, 151.01, 158.89, 162.29, 168.87. IR (KBr, cm^−1^): 1331 (N = C-S), 1417 (C = N), 3305 (NH). HRMS *m/z* \[*M*+H\]^+^ calcd for C~18~H~17~N~3~O~2~S: 340.108; found: 340.115.

Ethics statement {#sec012}
----------------

The experimental protocols were in accordance with the Ethical Principles in Animal Research adopted by the Brazilian College of Animal Experimentation (COBEA) and the protocol/experiments have been approved by the Ethics Committee for Animal Experimentation of Institute Butantan (CEUA Nº 1777050816).

Maintenance of parasite life cycle {#sec013}
----------------------------------

The BH strain of *S*. *mansoni* (Belo Horizonte, Brazil) was maintained in the intermediate snail host *Biomphalaria glabrata* and the golden hamster (*Mesocricetus auratus*) was used as definitive host. Female hamsters aged 3--4 weeks, freshly weaned, weighing 50--60 g, were housed in cages (30x20x13cm) containing a sterile bed of wood shavings. A standard diet (Nuvilab CR-1 Irradiada, Quimtia S/A, Paraná, Brazil) and water were made available *ad libitum*. The room temperature was kept at 22 ± 2°C and a 12:12 hour light--dark cycle was maintained. Hamsters were infected by exposure to a *S*. *mansoni* cercariae suspension containing approximately 200--250 cercariae using the ring technique \[[@pone.0225425.ref026]\]. After 49 days of infection, the *S*. *mansoni* adult worms were recovered by perfusion of the hepatic portal system \[[@pone.0225425.ref027]\]. Cercariae were released from infected snails and mechanically transformed to obtain schistosomula *in vitro* \[[@pone.0225425.ref028]\].

Treatment of schistosomula and adult worms with NJ series compounds {#sec014}
-------------------------------------------------------------------

Newly transformed schistosomula (NTS) were maintained for 2 h in M169 (Vitrocell) medium supplemented with 2% fetal bovine serum (FBS) (Vitrocell), 1 μM serotonin, 0.5 μM hypoxanthine,1 μM hydrocortisone, 0.2 μM triiodothyronine, penicillin/streptomycin, amphotericin, gentamicin (Vitrocell) at 37°C and 5% CO~2~ \[[@pone.0225425.ref028]\]. Only after 2 h incubation in culture medium the NJ series treatment was initiated as follows: 6.25 μM, 12.5 μM, 25 μM or 50 μM compound, for 1--5 days. Paired adult worms freshly perfused from infected hamsters (see above) were maintained in culture in RPMI medium (Gibco) supplemented with 10% fetal bovine serum (FBS) (Vitrocell), penicillin/streptomycin, amphotericin, gentamicin (Vitrocell) at 37°C and 5% CO~2~ for 2 h prior to the beginning of treatment with NJ series compound as follows: 12.5 μM, 25 μM or 50 μM compound, for 1--3 days of treatment. In all cases, NJ series compounds were prepared from a stock solution of 20 mM in dimethyl sulfoxide (DMSO), and the equivalent amount of DMSO was added to the control assays.

Motility assay of adult worms {#sec015}
-----------------------------

To evaluate the general condition of adult worms, including motility and mortality rate an inverted microscope was used. Parasites were observed after 1, 2 and 3 days of treatment with different concentrations of NJ series compounds or vehicle DMSO at 0.1%. Motility and survival of worms were assessed according to the criteria scored in a viability scale of 0--3 \[[@pone.0225425.ref029]\]. The scoring system was as follows: 3, complete body movement; 1.5, partial body movement or immobile but alive; and 0, dead. Treatment was considered lethal whenever no worm movement was detected when observed for 2 min. Oviposition and pairing status were also observed and eggs were counted.

Viability assay of schistosomula and adult worms {#sec016}
------------------------------------------------

Viability of schistosomula and *S*. *mansoni* adult worms after treatment was determined by a cytotoxicity assay based on the CellTiter-Glo® Luminescent Cell Viability Assay kit (G7570, Promega, Madison, Wisconsin, EUA) \[[@pone.0225425.ref030]\]. The assay determines the amount of ATP present in freshly lysed adults or in intact schistosomula; the assay signals the presence of metabolically active cells.

In addition, the viability of schistosomula was evaluated by the presence or absence of dead parasites, through staining with propidium iodide (PI) \[[@pone.0225425.ref031]\]. Schistosomula were equally distributed in 96-well microtiter plates, incubated with different concentrations of NJ05 + NJ07 compounds indicated in the figure or the corresponding DMSO vehicle (control), and 2 μg/mL propidium iodide (PI) (Sigma-Aldrich) were added at 2 days of drug exposure. The parasites were immediately observed with light microscopy at 10 x magnification using a Nikon Eclipse fluorescence inverted microscope. Under fluorescence microscopy, schistosomula death was scored by a red fluorescence signal (572 nm emission microscope filter) \[[@pone.0225425.ref031],[@pone.0225425.ref032]\]. The number of biological replicates that were assayed, as well as the number of parasites that were counted per replicate, is stated in the legends to the figures.

Cytotoxicity evaluation of NJ05, NJ07 or NJ05 + NJ07 in HEK293 and HES human cell lines {#sec017}
---------------------------------------------------------------------------------------

HEK293 (Human Embryo Kidney- HEK-293 -ATCC CRL-1573) and HES (human endometrial epithelial cell line, kindly provided by Prof. Douglas Anthony Kniss---Ohio State University, USA) \[[@pone.0225425.ref033]\] cell cultures (5x10^3^ cells/well) were incubated for two days with different concentrations of NJ05, NJ07 or NJ05+NJ07 (3.125 μM---400 μM), and after treatment their viability was measured by ATP quantitation with the CellTiter-Glo Luminescent Cell Viability Assay (G7570, Promega, Madison, Wisconsin, EUA). The data was used for calculating the EC50 with Origin software (OriginLab, Northampton, MA). All experiments were performed with 3 biological replicates.

Scanning electron microscopy (SEM) {#sec018}
----------------------------------

Adult worms collected by perfusion were immediately transferred to supplemented RPMI medium; parasites were distributed in 6-well plates (adults: 10 paired worm couples per well) with medium. The worms were kept in culture (oven at 37°C and 5% CO~2~) for 2 h for adaptation, and then NJ series compounds or the equivalent amount of 0.1% DMSO vehicle were added.

Ultrastructural analysis was performed with scanning electron microscopy. Adult worms incubated at different concentrations of NJ series compounds or with 0.1% DMSO vehicle for 1 and 2 days were fixed with modified Karnovsky reagent (1% paraformaldehyde, 2.5% glutaraldehyde, 1 mM calcium chloride in 0.1 M sodium cacodylate buffer, pH 7.4) and after the fixing stage the material was washed with sodium cacodylate buffer (0.1 mol / L, pH 7.2) and post-fixed with 1% osmium tetroxide (w / v) for 1 h.

Samples were dehydrated with increasing concentrations of ethanol and then dried with liquid CO~2~ in a critical-point dryer machine (model Leica EM CPD030, Leica Microsystems, Illinois, USA). Treated specimens were mounted on aluminum microscopy stubs and coated with gold particles using an ion-sputtering apparatus (model Leica EM SCD050, Leica Microsystems, Illinois, USA) \[[@pone.0225425.ref034]\]. Specimens were then observed and photographed using an electron microscope (FEI QUANTA 250, *Thermo Fisher Scientific*, *Oregon*, USA).

RT-qPCR validation of *S*. *mansoni* developmental genes {#sec019}
--------------------------------------------------------

For quantitative RT-PCR, complementary DNAs were obtained by reverse transcription (RT) of 50 ng adult worms total RNA using SuperScript IV Reverse Transcriptase (Invitrogen) and random hexamer primers in a 20 μL volume, according to the manufacturer's recommendations. The resulting cDNA was diluted 8-fold in water and qPCR amplification was done with 2.5 μL of diluted cDNA in a total volume of 10 μL using SYBR Green Master Mix (Life Technologies) and specific primer pairs ([S1 Table](#pone.0225425.s002){ref-type="supplementary-material"}). Tested genes were described in previous publications from the literature \[[@pone.0225425.ref035]--[@pone.0225425.ref040]\] or selected here based on their predicted function; primers were designed with the use of Primer3 online software. The Light cycle 480 II (Roche) qPCR was used. Results were analyzed by comparative Ct method and the statistical significance was calculated with the two-sided t-test.

To find adequate normalizer genes for qPCR, we looked for evidence of genes with non-detectable changes in expression upon NJ series compounds treatment; ten genes were selected based on literature reports \[[@pone.0225425.ref035]--[@pone.0225425.ref040]\] and tested by qPCR in the adult female worms for the lack of effect of NJ series compounds on their levels of expression. The two least affected genes were Mitochondrial 28s ribosomal protein s14 (Smp_090920) and PI3K regulatory subunit 4 (Smp_123610). In all cases, the geometric mean expression of these two genes was used as normalizer for calculating the expression levels of genes of interest.

Results {#sec020}
=======

Phenotypic effects of NJ series compounds on *S*. *mansoni* schistosomula {#sec021}
-------------------------------------------------------------------------

Eight different dimethoxy-aryl thiazole derivatives (see [Fig 1](#pone.0225425.g001){ref-type="fig"}) were tested for schistosomicidal properties against schistosomula early forms of the parasite. For this, schistosomula were first mechanically transformed from cercariae and were pre-incubated for 2 h in culture medium prior to compound addition. After each compound was added, schistosomula viability was evaluated every day for a period of five days by measuring the concentration of ATP in the metabolically active cells of the parasite. Different concentrations of each compound from 6.25 to 50 μM were tested, and out of the eight compounds that were assayed ([Fig 2A](#pone.0225425.g002){ref-type="fig"} and Fig A in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}), two had a more prominent effect in reducing schistosomula viability, namely NJ05 and NJ07 ([Fig 2A](#pone.0225425.g002){ref-type="fig"}). These compounds decreased the parasites' viability by approximately 40% after five days of exposure ([Fig 2A](#pone.0225425.g002){ref-type="fig"}). In order to test for a combinatorial effect, the best two compounds were assayed together. Within the first day of treatment with NJ05 + NJ07, across all concentrations tested (12.5, 25 or 50 μM) there was a dose-dependent decrease of 60 to 80% in parasite viability ([Fig 2B](#pone.0225425.g002){ref-type="fig"}), indicating a combinatorial effect between the two compounds. The phenotype was more prominent after five days of treatment, with viability reduced to zero ([Fig 2B](#pone.0225425.g002){ref-type="fig"}).

![Effect of NJ05, NJ07 or NJ05 + NJ07 on schistosomula viability.\
**(A and B)** ATP quantitation using a luminescent assay to assess schistosomula viability under NJ series compounds exposure. Schistosomula (100-120/well) were incubated with the indicated concentrations of NJ05, NJ07, NJ05 + NJ07 or with vehicle (0.1% DMSO) for up to 5 days. Viability was expressed as % luminescence values relative to the control (DMSO). Mean ± SEM from three biological replicate experiments are shown. The two-way ANOVA test was used to calculate the statistical significance (\*p *\<* 0.05; \*\*p *\<* 0.01; \*\*\*p *\<* 0.001). For clarity purposes, we show only the highest p-value obtained from the two-way ANOVA test for each time point on all different concentrations tested. **(C)** Quantitation of schistosomula viability using propidium iodide staining; schistosomula were treated for two days with NJ05 + NJ07 at the different concentrations indicated. Percentage of viable schistosomula (non-stained with propidium iodide) is shown. For each condition tested, about 400 schistosomula were used, divided into four biological replicates. Mean ± SEM from four replicate experiments are shown. **(D)** Schistosomula treated with the indicated concentrations of NJ05 + NJ07 or with vehicle (0.1% DMSO) for 2 days were visualized by staining with propidium iodide (marker of dead cells; 572 nm emission filter microscope). For each concentration (indicated at the top), the upper panel shows a light microscopy image and the bottom panel shows the image of the same field with differential fluorescence detection of PI-positive parasites. Bar = 100 μm.](pone.0225425.g002){#pone.0225425.g002}

The effect on schistosomula viability over 5 days of exposure to each of the other six NJ series compounds is shown at Fig A in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}; a less marked 10 to 40% reduction in parasite viability was observed.

Propidium iodide (PI) was used as an alternate method to quantitate viability of schistosomula after a 2-days incubation in the presence of control vehicle (0.1% DMSO) or of 6.25 to 50 μM of the best two compounds together (NJ05 + NJ07) ([Fig 2C and 2D](#pone.0225425.g002){ref-type="fig"}). Under fluorescence microscopy, dead schistosomula were detected by a red fluorescence signal from PI (536 nm emission microscope filter) ([Fig 2D](#pone.0225425.g002){ref-type="fig"}, lower panels). Total number of schistosomula present in the field was detected and counted under light optical microscopy at each NJ05 + NJ07 concentration ([Fig 2D](#pone.0225425.g002){ref-type="fig"}, upper panels), and the percentage viability was computed and plotted as shown in [Fig 2C](#pone.0225425.g002){ref-type="fig"}; mortality was 100% with 25 or 50 μM NJ05 + NJ07. Incubation with control vehicle (0.1% DMSO) for 2 days showed no reduction in parasite viability ([Fig 2B and 2D](#pone.0225425.g002){ref-type="fig"}, first upper and lower panels).

Effects of NJ series compounds on *S*. *mansoni* adult worms' viability and motility {#sec022}
------------------------------------------------------------------------------------

In order to evaluate the schistosomicidal activity of all eight compounds on adult worms the oviposition, male-female pairing status, worms' viability, motility, and alterations in the tegument were measured. Compounds were tested at a concentration range of 12.5 to 50 μM and observed every day for a period of 3 days.

Again, compounds NJ05, NJ07 or NJ05 + NJ07 exhibited the highest schistosomicidal activities among the eight tested, showing a concentration-dependent significant decrease in viability of the adult worms, as evaluated by ATP quantitation ([Fig 3A--3C](#pone.0225425.g003){ref-type="fig"}). Compound NJ05 was more effective than NJ07, and viability after three days was reduced to 25% in parasites treated with 50 μM NJ05 ([Fig 3A](#pone.0225425.g003){ref-type="fig"}), compared with a viability reduction to 60% with 50 μM NJ07 ([Fig 3B](#pone.0225425.g003){ref-type="fig"}). No combinatorial effect was detected when the two compounds were tested together (NJ05 + NJ07), as the viability was reduced to approximately 25% after three days of exposure to 50 μM NJ05 + NJ07 ([Fig 3C](#pone.0225425.g003){ref-type="fig"}), similar to the reduction caused by NJ05 only. The effect of other tested compounds is shown at Fig B in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}; after three days of treatment with compounds NJ03, NJ04 or NJ08 (at 50 μM concentration), a reduction in viability to only 75% was observed.

![*In vitro* effects of NJ05, NJ07 or NJ05 + NJ07 on the viability and motility of *Schistosoma mansoni* adult worms.\
**(A---C)** Viability was estimated by the total amount of ATP available in the parasites, using a luminescent assay. Pairs of adult worms were treated for 2 days with NJ05, NJ07 or NJ05 + NJ07 at the different concentrations indicated or with vehicle (0.1% DMSO). Viability was expressed as percentage luminescence values relative to the control (DMSO). Mean ± SEM from three replicate experiments are shown, each with 10 worm pairs. **(D---F)** Percentage of relative motility of adult worms treated with different concentrations of NJ05, NJ07 or NJ05 + NJ07 and controls (0.1% DMSO) at different times of exposure from 1 to 3 days. Mean ± SEM of three experiments, each with 10 worm pairs. \*p \< 0.05, \*\*p \< 0.01 and \*\*\* p \< 0.001 compared with controls. For clarity purposes, we show only the highest p-value obtained from the two-way ANOVA test for each time point on all different concentrations tested.](pone.0225425.g003){#pone.0225425.g003}

*S*. *mansoni* adult worms exhibited a larger decrease in motility when exposed to NJ05 or NJ05 + NJ07, compared with NJ07 treatment alone. This phenotype was dependent upon concentration and incubation time ([Fig 3D--3F](#pone.0225425.g003){ref-type="fig"}). After three days with the lowest concentration tested (12.5 μM), NJ05 or NJ05 + NJ07 decreased the motility to 40--50% compared with controls ([Fig 3D and 3F](#pone.0225425.g003){ref-type="fig"}), while NJ07 treatment at the same concentration led to a reduction of only 15--20% in motility ([Fig 3E](#pone.0225425.g003){ref-type="fig"}). Impairment of the peristaltic movement and reduced ability of the suckers to adhere to the bottom of the culture plates were observed. Among the other compounds of the NJ series tested we can highlight the 50% decrease in motility of adult worms exposed to 50 μM NJ03 or NJ08 after three days of exposure (Fig C in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}).

Effects of NJ series compounds on *S*. *mansoni* adult worm couples pairing and female oviposition {#sec023}
--------------------------------------------------------------------------------------------------

Compound NJ05 showed a more pronounced effect than NJ07 on worm couples pairing ([Fig 4A and 4B](#pone.0225425.g004){ref-type="fig"}). Thus, couples exposed for one day to 25 μM or 50 μM NJ05 already exhibited no pairing ([Fig 4A](#pone.0225425.g004){ref-type="fig"}), whereas there was no couple pairing reduction at day one with 25 μM NJ07, and with 50 μM NJ07, pairing was reduced to approximately 60% compared with control ([Fig 4B](#pone.0225425.g004){ref-type="fig"}). Combination of NJ05 + NJ07 was not effective in enhancing couples unpairing ([Fig 4C](#pone.0225425.g004){ref-type="fig"}) when compared with NJ05 alone. Among other NJ series compounds (see Fig D in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}), it can be highlighted the unpairing of approximately 75% - 90% of adult worm couples after three days exposure to 50 μM NJ03, NJ04, NJ08 or NJ11.

![*In vitro* effects of NJ05, NJ07 or NJ05 + NJ07 on pairing and oviposition of *Schistosoma mansoni* adult worms.\
**(A-C)** We monitored the pairing of control couples and of couples treated with different concentrations of NJ05, NJ07 or NJ05 + NJ07 at different times of exposure from 1 to 3 days. Mean ± SEM of three experiments are shown, each with 10 worm pairs. **(D-F)** Number of eggs released by females incubated with NJ05, NJ07 or NJ05 + NJ07 at different concentrations or with vehicle (0.1% DMSO) at different times of exposure from 1 to 3 days. \*p \< 0.05, \*\*p \< 0.01 and \*\*\* p \< 0.001. For clarity purposes, we show only the highest p-value obtained from the two-way ANOVA test for each time point on all different concentrations tested.](pone.0225425.g004){#pone.0225425.g004}

In addition, oviposition was extremely affected by treatment with the NJ series compounds, especially NJ05, NJ07 or NJ05 + NJ07 ([Fig 4D--4F](#pone.0225425.g004){ref-type="fig"}). Of note, reduction in oviposition was independent from couple unpairing. Thus, at concentrations of 25 μM or 50 μM, oviposition reached almost zero with NJ05, NJ07 or NJ05 + NJ07 already at day one ([Fig 4D--4F](#pone.0225425.g004){ref-type="fig"}), even when unpairing was incomplete or not present such as with NJ07 (compare [Fig 4B and 4E](#pone.0225425.g004){ref-type="fig"}). Results for oviposition reduction of the other tested compounds are described at Fig E in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}; little effect was observed in oviposition with these other compounds.

EC50 assay of NJ05, NJ07 or NJ05 + NJ07 in HEK293 and HES human cell lines {#sec024}
--------------------------------------------------------------------------

Toxicity of the compounds was evaluated by ATP quantitation on human HEK293 embryonic kidney cell line and human HES endometrial epithelial cell line in culture, after exposure for two days to 3.125--200 μM NJ05, NJ07 or NJ05 + NJ07. The concentrations of NJ05, NJ07 or NJ05 + NJ07 that caused a 50% reduction in viability (EC50) of HEK293 cells were 46.64 μM, 92.35 μM, and 18.42 μM, respectively (Fig F in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}). And for HES cell line the EC50 with NJ05, NJ07 or NJ05 + NJ07 were 133.53 μM, 145.20 μM and 29.59 μM, respectively (Fig F in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}).

Scanning electron microscopy of treated adult worms {#sec025}
---------------------------------------------------

Through scanning electron microscopy (SEM) it was possible to detect phenotypic alterations between control and treated adult worms. Control adult male schistosomes that were not exposed to any drugs are depicted in [Fig 5](#pone.0225425.g005){ref-type="fig"} (panels 1--4) and [Fig 6](#pone.0225425.g006){ref-type="fig"} (panels 1--4) and showed a normal topography of the surface membrane of anterior and dorsal regions, respectively. Oral and ventral suckers could be clearly visualized ([Fig 5](#pone.0225425.g005){ref-type="fig"}, panels 2--4). In the anterior portion of the body, the gynecophoral canal, a longitudinal fold of the middle and posterior body that houses the female for the purpose of mating and reproduction, could be identified ([Fig 5](#pone.0225425.g005){ref-type="fig"}, panel 2). In [Fig 6](#pone.0225425.g006){ref-type="fig"}, panels 1 to 4, the medial and posterior parts of schistosomes are shown, respectively. In these regions, a large number of tubercles with typical spines and ciliated papillae was observed ([Fig 6](#pone.0225425.g006){ref-type="fig"}, panels 2 and 3).

![Micrographs showing alterations on the ultrastructure of the anterior region of *Schistosoma mansoni* adult male worms exposed to NJ05 or NJ07.\
Scanning electron microscopy of worms exposed for 2 days to 25 μM NJ05 (panels 5--8), 25 μM NJ07 (panels 9--12) or vehicle (0.1% DMSO) (panels 1--4). Note that the size scale bar is shown within the black thin line below each image; **panels 1 and 2**: Control worms (Bar = 500 μm; 100 μm) presented the fully paired couple; **panels 3 and 4**: Anterior region of control male presented normal oral and ventral suckers tegument (Bar = 50 μm; 30 μm); **panels 5 and 6**: Anterior region of adult male worm treated with 25 μM NJ05 (Bar = 500 μm; 100 μm); **panels 7 and 8**: Male oral and ventral suckers presented tegument peeling (Bar = 50 μm); **panels 9 and 10:** Anterior region of male adult worm treated with 25 μM NJ07 (Bar = 500 μm; 100 μm); **panels 11 and 12**: Male oral and ventral suckers presented tegument without structural alterations (Bar = 50 μm). *f*: *female; os*: *oral sucker; vs*: *ventral sucker; gc*: *gynecophoral canal*; *la*: *lesion area; cp*: *ciliated papillae*.](pone.0225425.g005){#pone.0225425.g005}

![Scanning electron micrographs of dorsal and posterior regions of *Schistosoma mansoni* adult male worm exposed to NJ05 or NJ07.\
Worms were exposed for 2 days to 25 μM NJ05 (panels 5--8), 25 μM NJ07 (panels 9--12) or vehicle (0.1% DMSO) (panels 1--4). **Panels 1 to 4**: Medial (panels 1--3) and posterior (panel 4) regions of control male worm presented normal tegument (Bar = 50 μm; 20 μm; 5 μm; 50 μm). Note that the size scale bar is shown within the black thin line below each image. **Panels 5 to 7**: Enlarged view of dorsal region of adult male worm treated with NJ05 showing tegument lesions and loss of tubercles (Bar = 50 μm; 20 μm; 5 μm; 50 μm); **panel 8**: Posterior region of male adult worm treated with NJ05 showing lesion areas (Bar = 50 μm); **panels 9 to 11**: Dorsal region of male adult worm treated with NJ07 showed bubbles throughout (Bar = 30 μm; 20 μm; 5 μm; 50 μm); **panel 12**: Posterior region of male adult worm treated with NJ07 (Bar = 50 μm). *cp*: *ciliated papillae; b*: *blebs; tb*: *tubercles; la*: *lesion area*.](pone.0225425.g006){#pone.0225425.g006}

SEM revealed detailed surface membrane ultrastructural damage on the anterior ([Fig 5](#pone.0225425.g005){ref-type="fig"}) and dorsal ([Fig 6](#pone.0225425.g006){ref-type="fig"}) regions of adult male worms caused by *in vitro* exposure for 2 days to 25 μM NJ05 (Figs [5](#pone.0225425.g005){ref-type="fig"} and [6](#pone.0225425.g006){ref-type="fig"}, panels 5--8) or NJ07 (Figs [5](#pone.0225425.g005){ref-type="fig"} and [6](#pone.0225425.g006){ref-type="fig"}, panels 9--12) compared with controls (0.1% DMSO) (Figs [5](#pone.0225425.g005){ref-type="fig"}, and 6, panels 1--4). Thus, incubation of adult male *S*. *mansoni* worms with NJ05 resulted in severe tegument destruction of the anterior region ([Fig 5](#pone.0225425.g005){ref-type="fig"}, panels 5--8). In the ventral anterior region, focal lesions were observed in the oral and ventral suckers ([Fig 5](#pone.0225425.g005){ref-type="fig"}, panels 7 and 8). In the anterior portion of the body exposed to NJ07 the tegument showed no alterations ([Fig 5](#pone.0225425.g005){ref-type="fig"}, panels 9--12), and exhibited numerous ciliated papillae similar to the control ([Fig 5](#pone.0225425.g005){ref-type="fig"}, panels 1--4).

Severe damage to the dorsal surface of adult male schistosomes was induced by incubation for 2 days with NJ05 ([Fig 6](#pone.0225425.g006){ref-type="fig"}, panels 5--8) or NJ07 ([Fig 6](#pone.0225425.g006){ref-type="fig"}, panels 9--12). After NJ05 treatment, deterioration of the dorsal tegument was observed at higher magnification ([Fig 6](#pone.0225425.g006){ref-type="fig"}, panels 5--7), with the presence of lesion areas and loss of numerous tubercles and spines that covered the whole body of the parasite. In the posterior region, focal lesions along the body became evident ([Fig 6](#pone.0225425.g006){ref-type="fig"}, panel 8). Countless bubbles and loss of ciliated papillae were observed in the dorsal region of male worm exposed to NJ07 ([Fig 6](#pone.0225425.g006){ref-type="fig"}, panels 9--11); tegument at the male worm posterior region had no structural alterations ([Fig 6](#pone.0225425.g006){ref-type="fig"}, panel 12). Similar structural changes were already detected in adult male worms exposed for only 24 h to NJ05 or NJ07, with a more pronounced effect of NJ05 (Fig G in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}).

Control females incubated with vehicle (0.1% DMSO) showed a normal surface ([Fig 7](#pone.0225425.g007){ref-type="fig"}, panels 1--4). In females treated with 25 μM NJ05 for 2 days, severe damage to the dorsal tegument was visualized ([Fig 7](#pone.0225425.g007){ref-type="fig"}, panels 6--8), and exhibited extensive sloughing that exposed subtegumental tissues. Presence of blisters could be seen throughout the extension of the dorsal region of female exposed to 25 μM NJ07 for 2 days ([Fig 7](#pone.0225425.g007){ref-type="fig"}, panels 10--12).

![Damaged dorsal surface of *S*. *mansoni* adult female worms exposed to NJ05 or NJ07.\
Female worms were exposed for 2 days to 25 μM NJ05 (panels 5--8), 25 μM NJ07 (panels 9--12) or to vehicle (0.1% DMSO) (panels 1--4) and were observed by scanning electron microscopy; note that the size scale bar is shown within the black thin line below each image. **panel 1:** Low magnification image of female control worm (Bar = 500 μm). **panels 2 to 4:** Images of female control worms dorsal region, with normal structural appearance (Bar = 40 μm; 10 μm and 4 μm); **panel 5:** Low magnification image of female worm exposed to NJ05 (Bar = 500 μm); **panels 6 to 8:** Middle dorsal region of female presented apparent surface damage with peeling of the tegument membrane (Bar = 50 μm; 10 μm and 5 μm); **panel 9:** Low magnification image of female worm exposed to NJ07 (Bar = 500 μm); **panels 10 to 12:** Dorsal region of female worm presented bubbles along the tegument (Bar = 30 μm; 10 μm and 4 μm). *p*: *peeling; la*: *lesion area; b*: *blebs*.](pone.0225425.g007){#pone.0225425.g007}

Assessment by quantitative PCR of the expression of genes involved with vitellaria and female reproduction {#sec026}
----------------------------------------------------------------------------------------------------------

Since a strong reduction on oviposition was observed after treatment with NJ series compounds, a set of six genes that are involved in egg formation and participate in cell differentiation was selected for assessment of their possible change in expression by RT-qPCR. Tested genes involved in egg biosynthesis were all confirmed by RT-qPCR as downregulated in females treated with 25 μM NJ05 for 2 days ([Fig 8](#pone.0225425.g008){ref-type="fig"}), with a significant reduction in expression of p14, Tyrosinase 2, p48 and fs800. Two other genes tested by qPCR showed non-statistically-significant changes; they were the Egg Shell Protein (ESP) gene, and the Nanos 2 gene, which is involved in vitelline cell differentiation \[[@pone.0225425.ref041]\]. It is evident that NJ05 had a direct effect on the expression level of selected genes that are involved with eggshell formation and egg development in *S*. *mansoni* females \[[@pone.0225425.ref041]\].

![Vitellaria and female reproduction gene expression inhibition in adult females upon NJ05 treatment.\
Adult couples were treated with NJ05 (25 μM) or with vehicle DMSO (0.1%) for 2 days. The parasites were stored in RNAlater (Ambion) for further processing. All parasite couples were separated and only the females had their RNA extracted followed by cDNA synthesis. The genes measured by RT-qPCR were Smp_131110 (p14), Smp_000430 (Egg Shell Protein (ESP)), Smp_013540 (Tyrosinase 2 (Tyr 2)), Smp_014610 (p48), Smp_000290 (fs800), Smp_055740 (Nanos 2). The geometric mean from two reference genes (Smp_090920 and Smp_123610) was used for normalization with the DCT method. The plotted data is retrieved from DDCT analyses in which the DMSO-treated sample is the control. Significant fold-change in gene expression between DMSO and NJ05 treatment is shown by the numbers inside the brackets. Mean ± SEM of four replicates is shown. Student unpaired parametric two-sided t-test was used, and statistically significant differences are represented by the asterisks. \*p ≤ 0.05; \*\*p ≤ 0.01.](pone.0225425.g008){#pone.0225425.g008}

The effect of NJ07 or NJ05 + NJ07 on the expression of the same set of six genes was also tested; worms were treated for 2 days with 25 μM NJ07 or NJ05 + NJ07; the only gene detected by RT-qPCR as significantly 2.8--2.9 X downregulated in females under both treatments was Nanos 2, a gene related to cell differentiation (Fig H in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}). Although oviposition was impaired in both treatment conditions (see [Fig 4E and 4F](#pone.0225425.g004){ref-type="fig"}), there was no significant change in expression caused by both treatments among the five tested genes related to eggshell formation and egg development (Fig H in [S1 Text](#pone.0225425.s001){ref-type="supplementary-material"}), indicating that other genes may have been affected by the treatment.

Discussion {#sec027}
==========

Chemotherapy is the only immediate recourse for minimizing the prevalence of schistosomiasis, and currently it involves predominately the administration of a single drug, praziquantel (PZQ). There is an important limitation of the therapeutic profile of PZQ, as it lacks activity against larval developing stages of the parasite; therefore, retreatment is necessary to kill those parasites that have since matured \[[@pone.0225425.ref021],[@pone.0225425.ref042]\]. The present study was performed to evaluate the *in vitro* schistosomicidal effect of the aryl-thiazole derivatives both on adults and on the larval developing stages of the parasite. The following schistosomicidal parameters were analyzed: viability, motility, oviposition, mortality and morphological changes, which are indicators commonly used for evaluating the schistosomicidal effect of new chemical entities \[[@pone.0225425.ref043],[@pone.0225425.ref044]\]. In light of the parasite biology and according to the evaluation of these parameters, schistosomicidal activity can be effective essentially in three different ways: causing schistosomula death, thus preventing host infection, inhibiting oviposition that could lead to a decrease in the pathological phenotype of schistosomiasis (hepato- and splenomegaly), and causing adult worm's death \[[@pone.0225425.ref044],[@pone.0225425.ref045]\]. All three of the above schistosomicidal effects were present in our *in vitro* assays with NJ compounds, suggesting that further exploration of this class of aryl-thiazole derivatives is warranted.

The aryl-thiazole compounds evaluated in this study are differentiated, in principle, by the substitution pattern of the phenyl ring directly attached to the hydrazine portion (2,4-dimethoxy-phenyl and 3,4,5-trimethoxy-phenyl). Trimethoxylated derivatives (NJ04, NJ05, NJ07 and NJ11) showed a better profile in reducing the viability of *S*. *mansoni* schistosomula and adult worms compared with the dimethoxylated ones (NJ03, NJ06, NJ08 and NJ012). One important chemical property of methoxy substituent is that its oxygen atom is an acceptor of proton for different types of hydrogen-bonds \[[@pone.0225425.ref046]\] favoring the biological activity of new compounds by improving the target recognition \[[@pone.0225425.ref047]\]. Besides, trimethoxy-substitution increases the electronic density, and this could also be related to the higher schistosomicidal activity of this class compared with the dimethoxylated ones. The results corroborate with studies involving other parasites such as *Plasmodium falciparum* \[[@pone.0225425.ref048]\], *Leishmania braziliensis* \[[@pone.0225425.ref049]\] and *Trypanosoma cruzi* \[[@pone.0225425.ref050]\], evidencing the importance of methoxy group trisubstituted aromatic nuclei for antiparasitic activity.

Additionally, the two aryl-thiazole series are discriminated by the presence of different substituents of the phenyl ring attached to the thiazole nucleus (hydrogen, 4-chloro, 4-bromo, 4-nitro). The best compounds evaluated in this study have 4-nitro (NJ05) and 4-bromo (NJ07). Notably, such substitutions reflect an increase in antiparasitic activity as described in the literature; Papadopoulou *et* al., 2016 \[[@pone.0225425.ref051]\] described the antitrypanosomal activity of 5-nitro-2-aminothiazole and demonstrated activity against *T*. *cruzi* amastigotes at nanomolar concentrations and was about 4-fold more potent than BNZ (benznidazole-reference drug). Generally, the biological activity of nitro compounds involves the biotransformation of the nitro group, releasing intermediates that disrupt the redox process. Some of those intermediates can attack enzymes, membranes and DNA, providing the basis for their mode of action, including those reported against parasites \[[@pone.0225425.ref052]\]. NJ compounds might have caused oxidative stress and the consequent biological activity observed here.

The insertion of halogen atoms, in turn, on the compound structure in the discovery phase of new drugs can lead to increased potency and selectivity of the pharmacological target by affecting the pKa, modulating the conformation, increasing hydrophobic interactions between the ligand and the target, increasing lipophilicity and favoring permeation in biological membranes \[[@pone.0225425.ref053],[@pone.0225425.ref054]\]. The increase in cellular permeability of the parasite membrane is an important feature for the action of a target drug; for example, PZQ is supposed to act on the voltage-gated calcium channels of schistosomes \[[@pone.0225425.ref055]\], but has also been shown to alter membrane fluidity in model membranes \[[@pone.0225425.ref056]\] and in the *S*. *mansoni* tegument \[[@pone.0225425.ref057]\], thus possibly increasing calcium permeability. The effects of para-substituents on biological activity can be explained by the hydrophobicity (π) and electronic effects (σ) as stated by Craig, 1971 \[[@pone.0225425.ref058]\]. Both NO~2~ and Bromo substituents present positive electronic (+ σ) and lipophilic (+ π) effects. This means inferior availability of free electron pairs, which could promote membrane permeation. The phenotypic effects observed over the course of NJ05 treatment on *S*. *mansoni* couples included reduction in motility, impairment of peristaltic movement and of the ability of their suction suckers to adhere to the bottom of the culture plates, thus generating weak contractions and subsequent paralysis. This may be a consequence of the perturbation in the influx of extracellular calcium, which in eukaryotic cells is a signal for motor events, besides playing an important role in the promotion of apoptosis \[[@pone.0225425.ref059]--[@pone.0225425.ref061]\]. Further studies are necessary to explore other structural aspects of these compounds besides their possible lipophilicity contribution to membrane permeabilization.

Changes in the general conditions of worms, including adult worms' motility and tegument damage visualized through high resolution scanning electron microscopy were observed after two days treatment with 25 μM NJ05 + NJ07. Motility assay and cytotoxicity evaluation by ATP quantification revealed an increase in the number of dead parasites that was concentration and time dependent following NJ05 + NJ07 treatment. Maximum death of adult worms occurred after three days of treatment at concentrations of 25 or 50 μM NJ05 + NJ07. Noteworthy, in schistosomula 100% death happened in the first two days (25 or 50 μM NJ05 + NJ07). The larvae presented lack of movement, granularity and shape alterations, showing that NJ05 + NJ07 combination was effective against younger forms of the parasite. This is of great importance, since the drugs of choice for treatment of schistosomiasis act on adult worms, having a small action on schistosomula \[[@pone.0225425.ref062]\].

Detailed microscopic observation showed that NJ05 or NJ07 were capable, separately, of inducing morphological alterations in the outer membrane of all adult worms tested in this work. We found extensive damage to the tegument in both male and female worms after 2 days of exposure to NJ05 or NJ07. Male adult worms of *S*. *mansoni* treated with NJ05 showed lesions of tegument and loss of tubercles; the females, in turn, demonstrated severe damage on the tegument surface with the presence of blisters and large peeling of the tegument. Upon NJ07 *in vitro* treatment the dorsal region of male and female adult worms showed bubbles in all their extension. Alterations in the surface ultrastructure of schistosome worms have been investigated by a number of authors in order to evaluate anti-schistosomal drugs \[[@pone.0225425.ref063]--[@pone.0225425.ref068]\]. Here, the alterations caused by NJ05 or NJ07 indicate that trimethoxy substituent and the presence of NO~2~ and Br substituents favored damage on male and female adult worms.

The compounds tested here appeared to influence adult females' oviposition, mainly NJ05 and NJ05 + NJ07, since no eggs at all were found in the culture medium after treatment under these two conditions. Eggs obtained from couples treated with NJ07 were smaller than control eggs and probably not viable due to their lack of germinal disks formation. In females treated with NJ05, the expression of genes related to egg biosynthesis including tyrosinase (SmTyr2) \[[@pone.0225425.ref069]\], and eggshell precursors such as p14 \[[@pone.0225425.ref070]\] and p48 \[[@pone.0225425.ref071]\] were found to be decreased in relation to the control.

Also, genes related to cell differentiation and development of the germinative line of metazoans such as Nanos 2 were found to have decreased expression in relation to the control in adult females treated with NJ05, NJ07 or NJ05 + NJ07. On platyhelminths, Nanos 2 is generally found to be expressed in the anterior portion of the ovary \[[@pone.0225425.ref041]\], where the oogonias are located \[[@pone.0225425.ref072]\], and it plays an essential role in the proper development, regeneration and maintenance of germ cells in several organisms \[[@pone.0225425.ref073]--[@pone.0225425.ref075]\].

Overall, the results indicate that thiazoles, especially those trimethoxylated derivatives are antiparasitic agents. These compounds showed substantial schistosomicidal properties against schistosomula and adult *S*. *mansoni* worms, with a significant reduction in viability, motility, pairing, survival rate, oviposition, severe alterations in the tegument and mortality of worms, and further biological studies are warranted to clarify the mechanisms of schistosomicidal action. It is important to emphasize that NJ05 + NJ07 had an intense activity against the young forms of *S*. *mansoni in vitro*, a characteristic not encountered in the drugs of choice for treatment of schistosomiasis such as PZQ and oxamniquine \[[@pone.0225425.ref008],[@pone.0225425.ref076]\].

Cytotoxic effect for HEK293 human embryonic kidney cell line was higher (EC50 of 46.64, 92.35 and 18.42 μM for NJ05, NJ07 and NJ05+NJ07, respectively) than the cytotoxic effect for HES somatic epithelial cell line (EC50 of 133.53, 145.20 and 29.59 μM for NJ05, NJ07 and NJ05+NJ07, respectively) suggesting that these compounds may be more effective in diminishing viability of embryonic cells that undergo proliferation than in somatic cells. Systematically, the combination between NJ05+NJ07 showed a cytotoxic effect higher than the compounds separately, but it is worth mentioning that the best compound in reducing viability of both schistosomula and adult worms was NJ05. Given that the EC50 for NJ05 in the HEK293 human cell line is in the medium micromolar range (46.64 μM), and in the HES human cell line the EC50 is in the high micromolar range (133.53 μM), this compound could be used as an aryl-thiazole prototype for the development of new schistosomicidal compounds in the future.
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PONE-D-19-21297

In vitro activity of aryl-thiazole derivatives against Schistosoma mansoni schistosomula and adult worms

PLOS ONE

Dear Professor Sergio Verjovski,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript was reviewed by three experts in the field. Despite the reviewers stating that the present report is in a good shape from a technical point of view, they claim that the manuscript must be revised before it is suitable for publication. In addition, cytotoxicity assays are required.

Although the results are preliminary, particularly due to the lack of in vivo studies, I believe that the study addresses an interesting question. In my view, resubmission of the manuscript is possible, but only if the comments that were raised are fully addressed by providing additional experiments that would be in line with the provided comments. 

We would appreciate receiving your revised manuscript by October 21, 2019. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Josué de Moraes, Ph.D.

Academic Editor

PLOS ONE

**Journal Requirements:**

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://doi.org/10.1371/journal.pntd.0006873>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.\"\"\"

3\. Please amend the subsection category "\[FOR JOURNAL STAFF USE ONLY\]" for your manuscript. Unfortunately, this is not a valid category. At this time, please choose one or more subsections that best represent the topic(s) of your study.

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript described the schistosomicidal activities of aryl-thiazole derivatives. Some of the data and expression in this manuscript are unclear and should be revised before it can be accepted for publication. My comments are listed below:

1- The manuscript is very difficult to read. Please organize the Material and Methods session. e.g. Title: \"Treatment of adult worms with NJ series compounds\".

Paragraph: \"Schistosomula and adult worms were treated with different concentrations of compounds from the NJ series in culture medium specific to each stage as indicated below\...\" (page 13). According to the results, adult worms and schistosomula treatments were performed under different conditions (incubation period), please make this information clear in the text;

2- It\'s very important to remind the necessity of cytotoxicity assay done to prove the absence of toxicity of the aryl-thiazole derivatives, before this manuscript to be accepted for publication;

3- It's widely studied the correlation between the effect of some drugs on S. mansoni motility through of classical studies. e.g. Hillman, G. R., Senft, A.W.J Pharmacol Exp Ther (1993), 119, 75-86.; Da Silva, S.P., Noel, E. Parasitol Res (1995), 81:543-548; Mendonça Silva, D. L. et al., Parasitology (2004), 129 : 1-10; Rinaldi, G. et al., Int J Parasitol-Drug (2015), 141e148; De Oliveira, R.N., Exp Parasitol (2012), 132,135--143.

In present study, motility and survival of worms were assessed according to the criteria of a nematode (Toxocara canis- ref 30), which are completely different from trematode. Please, why this choice? (Page 14, session "Motility assay\");

4- The order and description of the results session is very confusing to the reader;

5- In the Results session: \"Phenotypic effects of NJ series compounds of S. mansoni schistosomula\" (page 17). The description is very poor and confused;

6- In the Results session:"Fig 2. Synergistic effect of NJ05 + NJ07 on schistosomula viability (A and B) ATP" (page 17). It is extremely premature to describe this result as a synergistic effect of NJ05 + NJ07 compounds, considering that pharmacokinetic and pharmacodynamics mechanisms does not yet been studied. Please review this affirmation with caution;

7- Finally, in the results session \"Assessment by quantitative PCR of the expression of genes involved with vitellaria and female reproduction\" (page 23).

Whereas: \"Tested genes involved in egg biosynthesis were all confirmed by qPCR as downregulated in females treated with 25 μM NJ05 for 2 days (Fig 8), with a significant reduction in expression of p14, Tyrosinase 2, p48 and fs800 \".

Suggestion: It would be very interesting to observe the eggs viability by miracid hatching assay. e.g. Sarvel, A.K. Mem Inst Oswaldo Cruz (2006), 101 (Suppl. I): 289-292.

Major Revision

Reviewer \#2: REVIEWER COMMENTS ON THE MANUSCRIPT PONE -- D -- 19- 21297

The research article entitled "In vitro activity of aryl-thiazole derivatives against Schistosoma mansoni schistosomula and adult worms" reports the synthesis and the antischistosomal characterization of a series of aryl-thiazoles.

The article has distinction when regarding the quantity and quality of the biological assays performed as well as about the synthetic approach and the choice of this chemical class. It lacks, however, the important selectivity information of the compounds since, nowadays, to prove effectivity of a compound are not enough to establish the potential of it to be employed as a lead or even as a hit compound in drug discovery.

No mention about any kind of selectivity assays is present in this study. At least a cytotoxicity assay against some usual cell lines should be conducted, such as VERO, HaCAT or lymphocyte cells.

I also suggest, to a further submission, a careful review of the manuscript in the following aspects:

MATERIAL AND METHODS

Page 6:

Even the synthetic approach being well-known, it would be kind if the authors provided some important aspects of the synthesis, such as the molar proportion between the reagents and the molar excess of sodium acetate employed. Everyone who reads your article could, easily, reproduce the synthesis directly from it. Yet, regarding the reaction media, did the authors employ any solvent that allowed the reflux condition? If yes, please, provide this information along the experimental text.

I also seem as important to include some characterization information about the compounds, such as NMR and IR signals, melting point ranges, etc. The journal public include chemists which would like to be provided with this information. No spectra needed, however. Only the attributions would be enough.

RESULTS

Page 11: Figure 2. Remember to mention that the data did not correspond only to NJ05+NJ07 together but also to NJ05 and NJ07 individually. The Figure 2 title did not reflect the exhibited data.

Page 13: When discussing about decreasing in worm motility, it seems that NJ05+NJ07 together leaded to a higher decrease than NJ05 and NJ07 alone. Similarly to the discussed by the authors about the viability being decreased only by the NJ05, it seemed, to me, that the association decreases in motility was similar to the observed with NJ07 only. Please, review this data.

Page 14: Authors present the results of NJ07 on the worm pairing and oviposition. But, at the end of such discussion, they mention that the other compounds were able to result in impairments of 75 t0 90%. So, these compounds were better in modulate the worm pairing than NJ07 and that is exactly what Figure D from S1 text informs. For instance, NJ03 is better than NJ07 at 50 �M. So, why the authors have chosen NJ07 to discuss along the text and presented the better data in supplementary material?

It that is not the case, please review the phrase construction which induces the reader to understand what I stated.

DISCUSSION

Page 19: Authors constructed a parallel between their findings and the best ways to achieve antischistosomal activity:

"In light of the parasite biology and according to the evaluation of these parameters, schistosomicidal activity can be effective essentially in three different ways: causing schistosomula death, thus preventing host infection, inhibiting oviposition that could lead to a decrease in the pathological phenotype of schistosomiasis (hepato- and splenomegaly), and causing adult worm's death \[44, 45\]. All three of the above schistosomicidal effects were present in our in vitro assays with NJ compounds..."

Exactly by the fact that several different actions were observed, SELECTIVITY ASSAYS must be conducted, since it could be possible the existence of different mechanisms of actions which, in turn, could lead to potential side effects. This should be better explored by the authors and is a fundamental step to be accomplished to this article to be accepted.

Page 19: Authors did the following affirmation:

"Trimethoxylated derivatives (NJ04, NJ05, NJ07 and NJ11) showed a better profile in reducing the viability of S. mansoni schistosomula and adult worms. The main electronic change on the molecule caused by tri-substitution is an increase of the electronic density, and this effect significantly increased the schistosomicidal activity, also demonstrated by the synergic effect of compounds NJ05 + NJ07 which differ only by 4-nitro and 4-bromo substituents, respectively."

It is dangerous to correlates the action to the increase of the electronic density reached with the trimethoxy series, specially when this was the only aspect discussed.

Electronic effects could not be the only ones involved in the compound's behavior. The 3-OMe group, for instance, could be an important docking point to these compounds in a potential receptor. The right group at the right position could made an enormous difference in compounds activity. This is particularly true for hydrogen bond interaction, which could, for instance, be involved in the 3-MeO group (present only in the trimethoxy series) recognition by the worm's target. Please, review this statement.

It is true that the trimethoxy aromatic group has already being proved to be important for different antiparasitic activities, but not only by its electronic contributions.

Pages 19-20: Authors composed the hypothesis that "NJ compounds might have caused oxidative stress and the consequent biological activity observed here." Then they correlate the compound's action to a possible direct amino acid nitrosylation of SmTGR.

The problem is that nitrosylation processes are related to nitroso group (NO) and not to nitro group itself (NO2).

Nitro group usually suffers reduction up to the hydroxylamine and, further, to amine producing reactive oxygen and nitrogen species which, in turn, destroy DNA and other important cell subunits. It is an unspecific mechanism of action which is also related, sometimes, to unsuitable toxicity profiles.

Nitrosylation, on the other hand, implies the presence of a NO species or a NO donor species which, nitroaromatic systems such as the one studied here, do not produce in vivo.

Please, review this hypothesis.

Pages 20: In the statement "Permeation in biological membranes may have been fundamental for the good activity presented by NJ07." Be careful!

4-Cl would have been more active if membrane permeation would be such significant aspect since its hydrophobic contribution (� of Hansch = 0.70) is higher than that obtained with the 4-NO2 group (� of Hansch = 0.24) present in NJ05 structure.

You have limited experimental data to comment on the relationship between chemical structure and biological activity by now. Some comments would be interesting but always being careful to highlight the fact that further studies to explore other structural aspects should be performed.

Minor revisions include a careful review of the phrases constructions which are a little bit strange to the formal English.

Reviewer \#3: In this manuscript the authors report their work on synthesizing a series of thiazole derivatives and the assessment of the anthelmintic activity of 8 of these compounds in vitro. I feel that this description of their work is very thorough and their study design draws upon all of the best molecular techniques available to synthesize, interrogate and execute these particular class of studies. Their assessments of parasite motility and mortality, egg laying, adult worm pairing and parasite viability clearly demonstrate the antischistosomal activity of their compounds, especially compounds NJ05 and NJ07. The antischistosomal activity of compound NJ05 against juvenile worms shows particular promise given the lack of activity by the gold standard of treatment, praziquantel. The only reason for my suggestion of minor revision include some grammatical issues in the text (e.g. verb tense).

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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PONE-D-19-21297R1

Dear Dr. Verjovski-Almeida,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Josué de Moraes, Ph.D.

Academic Editor

PLOS ONE

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

10.1371/journal.pone.0225425.r004
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PONE-D-19-21297R1

In vitro activity of aryl-thiazole derivatives against Schistosoma mansoni schistosomula and adult worms

Dear Dr. Verjovski-Almeida:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Josué de Moraes

Academic Editor

PLOS ONE
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